INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
81.21
+3.09 (+3.96%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close78.12
Open78.52
Bid81.30 x 1400
Ask81.33 x 1000
Day's Range78.37 - 81.64
52 Week Range57.00 - 89.30
Volume1,437,531
Avg. Volume1,148,637
Market Cap17.372B
Beta (3Y Monthly)0.90
PE Ratio (TTM)57.15
EPS (TTM)1.42
Earnings DateOct 28, 2019 - Nov 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est93.56
Trade prices are not sourced from all markets
  • Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
    Zacks

    Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma

    Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.

  • GlobeNewswire

    BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia

    BERKELEY, Calif., Sept. 16, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in.

  • Is There An Opportunity With Incyte Corporation's (NASDAQ:INCY) 29% Undervaluation?
    Simply Wall St.

    Is There An Opportunity With Incyte Corporation's (NASDAQ:INCY) 29% Undervaluation?

    In this article we are going to estimate the intrinsic value of Incyte Corporation (NASDAQ:INCY) by taking the...

  • GlobeNewswire

    BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has upsized and closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under the Offering, the Company issued a total of 12,090,007 common shares at a price of C$0.07 per common share for gross proceeds of C$846,300.49.

  • Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
    Zacks

    Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA

    The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.

  • Why This Biotech Stock Has 'Limited Downside' After 25% Gain This Year
    Investor's Business Daily

    Why This Biotech Stock Has 'Limited Downside' After 25% Gain This Year

    Biotech company Incyte could parlay its drug, Jakafi, into $300 million in 2025 sales, an analyst said Thursday as he upgraded Incyte stock. Jakafi also is used to treat two forms of cancer.

  • Merck's Keytruda Combination Gets EC Nod for Kidney Cancer
    Zacks

    Merck's Keytruda Combination Gets EC Nod for Kidney Cancer

    Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.

  • GuruFocus.com

    Wall Street Green on Wednesday

    Navistar jumps on strong quarterly results Continue reading...

  • 10 Stocks to Buy for September
    InvestorPlace

    10 Stocks to Buy for September

    With August's trading winding down, we're heading into a month that's known to be problematic. The average September return for the S&P 500 is a loss of 0.62%, and it's down more often than it is up. And this year, we're heading into the month still overbought from the big bounceback from early in the year.It's a dangerous time to be taking on new long positions, but that danger doesn't necessarily apply across the board. There are a handful of stocks well-positioned to rally through what could be a bearish backdrop. * 7 Stocks to Buy Down 10% in the Past Week To that end, here's a rundown of the top stocks to buy for September, and perhaps beyond. In some cases these names are coming out of a prolonged lull, while others are seemingly stuck in unstoppable uptrends. In all cases though, the odds of standout strength are at least a little better than average. In no particular order …InvestorPlace - Stock Market News, Stock Advice & Trading Tips Activision Blizzard (ATVI)The final quarter of last year was a miserable one for Activision Blizzard (NASDAQ:ATVI), and its shareholders. Shares fell a total of 52% from peak to trough, as a couple of different missteps and missed opportunities took a toll. Namely, it didn't see "Fortnite" coming, and its "Black Ops 4" title wasn't as well-received as hoped.The meltdown served as something of a wake up call for the company. While there's still work to be done, the game publisher at least knows what's left to do.ATVI stock has also started to grind its way out of a hole, logging a string of higher lows since February's bottom, and working its way back above the important 200-day moving average line. On the verge of punching through resistance at $51.60, the pace of the rebound could perk up very soon. Visa (V)It's an unusually persistent gainer. Granted, the gains aren't necessarily red-hot and take a while to put in place. The rally also isn't without its occasional flaws and stumbles. By and large, any setbacks Visa (NYSE:V) suffers are shallow and short-lived, and there's a lot to be said for consistency. V stock is up nearly 130% since the end of 2016 thanks to its steady march forward.Now is a compelling time to step in too, after a small stumble that pulled Visa shares back from its early August high near $184 to a low of $167. All it took was a kiss of the 100-day moving average line, plotted in gray, to renew the rally. That may be all the dip we're going to get. * 7 Tech Industry Dividend Stocks for Growth and Income It's not a cheap stock, valued at 34 times its trailing earnings and more than 28 times next year's projected profit. A frothy valuation hasn't held Visa shares back at any point in its past though. Scorpio Tankers (STNG)Scorpio Tankers (NYSE:STNG) shares rolled over in 2015, and never looked back … until April of this year, when something clearly changed. STNG stock broke out of a long-standing and well-established rut. The company reported its first quarterly profit since 2016. Despite all the trade war noise and inconsistent pricing of crude oil, shipping rates improved enough to let the company book net earnings of 30 cents per share. That was more than twice what analysts were expecting.The enthusiasm that re-ignited STNG stock in April has since cooled. Take a closer look at the chart, however, and you'll see the 200-day moving average line, in white, is trying to renew the recovery effort.It's still one of the top stocks to buy for that reason, not to mention the shipping rates that improved enough to drive a swing to a profit are improving again after a summer lull. Darden Restaurants (DRI)The restaurant business isn't usually a highly profitable one. It's also an industry that's particularly vulnerable to recessions. But, Darden Restaurants (NYSE:DRI) is a proven operator. Assuming the chatter about a global economic headwind is more bark than bite, Darden's business will be fine.To that end, analysts are calling for more than 6% worth of sales growth this year, which should drive profits from last year's $5.82 per share to $6.40, and then on to $6.86 per share next year. * 10 Companies Using AI to Grow Arguably the biggest reason DRI stock has earned a spot on a short list of stocks to buy headed into September, however, is its reliable forward progress. It's hardly a straight line, but this is a name that has rewarded buyers who've stepped in on the dips like the one we're in the midst of making. NiSource (NI)It's not a fast mover, but what NiSource (NYSE:NI) lacks in speed it makes up for in reliability. Shares of the utility name are up more than 50% since the end of 2016, and investors didn't have to experience any seasickness to reap that reward.That being said, this chart started to take on a curious shape earlier this year, when it broke above the upper boundary of a converging wedge pattern, framed in blue, that had been guiding it upward since late-2015. Rather than peel back from it, NiSource shares have fought their way above it, using support found at the gray 100-day moving average line.It's got a lot to do with falling interest rates. But, inasmuch as rates are apt to remain suppressed for the foreseeable future on top of NiSource's history of steadily increasing payouts, NI stock could be a nice, safe place to tuck away some capital while the broad market gets its bearings. Kratos Defense & Security Solutions (KTOS)Kratos Defense & Security Solutions (NASDAQ:KTOS) is anything but a household name. With a modest market cap of only $2.1 billion, odds are good most investors have never even heard of it.Don't let its obscurity fool you though. This little defense contractor is getting real big, real fast. Revenue is projected to grow 18% this year, and then do the same in 2020, driving the bottom line from last year's 24 cents per share to 32 cents this year to a whopping 49 cents per share next year. * 7 Stocks the Insiders Are Buying on Sale The market appreciated this growth pace -- in spades -- in May of this year, but perhaps too much. That big rally set the stage for a wave of profit-taking. The selloff stopped and started to reverse once the 200-day moving average line was met last week though, making now a compelling time to step in. Old Republic International (ORI)If the name Old Republic International (NYSE:ORI) rings a bell but you can't quite remember why, think insurance. The company operates several different insurance businesses, some of which use the moniker, while others don't. Old Republic is also the parent of outfits like Great West Casualty Company and BITCO.For a variety of reasons ranging from interest rate turbulence to an inordinate number of devastating hurricanes, to the growing unpredictability of lifespans, the insurance industry has been an increasingly tough one to manage. Old Republic has made it look easy, consistently driving revenue growth while driving less consistent income growth for a decade now. Twelve-month revenue of $6.6 billion is markedly better than the twelve-month revenue tally of $5.5 billion from five years ago.That's a key part of the reason the stock has managed to make reliable, even if choppy, forward progress. It's an especially interesting prospect right now, as ORI stock is still closer to the bottom of its rising trading range than the top of it. Graphic Packaging Holding (GPK)Graphic Packaging Holding (NYSE:GPK) has taken shareholders on a roller coaster ride over the course of the past five years, from a high above $16 to a low below $10, yet is currently priced where it was as of late-2014.The market may have been unduly doubtful of Graphic Packaging's potential, particularly of late. This year's expected revenue growth of just under 3% isn't jaw-dropping, and next year's modeled 2.4% improvement is even less thrilling. Modest sales are driving less-modest earnings growth, however, of 6% this year and 15% in 2020, according to analysts. * 10 Marijuana Stocks That Could See 100% Gains, If Not More To that end, analysts believe investors are collectively undervaluing GPK stock. They rated it a little better than a "Buy," and hold a consensus target price of $16.70, versus its current price of $13.40. Incyte (INCY)Like most biopharmaceutical stocks, Incyte (NASDAQ:INCY) is no stranger to wide, prolonged swings. Shares rallied from around $65 in early 2016 to a high of $149 by early 2017, back to a low of around $58 late last year.If you can catch one of the stock's turning points though, it can lead to a big payoff. It looks like the stock's trying to make good on the bullish pivot that materialized in December. Though that bounce cooled in April and has since done nothing, a closer look makes clear that INCY stock is finding persistent support at its rising 200-day moving average line, plotted in white.There's still a key technical ceiling around $89, where Incyte shares peaked a couple of times this year. But, with double-digit sales growth expected this year and next thanks to strong interest in its relatively young cancer drug Jakafi, the odds of a breakout are a little too good to ignore. TE Connectivity (TEL)Finally, add TE Connectivity (NYSE:TEL) to your list of prospective stocks to buy before we get too deep into September.Like Kratos, TE Connectivity isn't exactly a household name, for a couple of reasons. Chief among them is the fact that it's based in Switzerland. The other is that it makes electronics components most people don't give a second thought to. Wires, heat shrink tubing, and cable connectors are all part of its portfolio. RF antennas would be considered the high-tech portion of its product menu.What it lacks in pizzazz, however, it makes up for in reliability. The advent of 5G wouldn't be taking shape without the simple pieces and parts TE Connectivity provides, but there's always some sort of electronics evolution that keeps TE Connectivity moving forward.One has to zoom way out to see it, but the push up and off of a long-term support line going back to 2009 has set the stage for a multi-year advance that has only just begun.As of this writing, James Brumley held long positions in NiSource and Activision Blizzard. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy Down 10% in the Past Week * 15 Retail Survivors to Buy for the Long Run * 7 Stocks That Wall Street Thinks Could Rise 50% Or More The post 10 Stocks to Buy for September appeared first on InvestorPlace.

  • Why Is Incyte (INCY) Down 4.2% Since Last Earnings Report?
    Zacks

    Why Is Incyte (INCY) Down 4.2% Since Last Earnings Report?

    Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
    Zacks

    Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

    Sector ETF report for PBE

  • GlobeNewswire

    BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced it will be featured as a presenting company at the 21st Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference.

  • Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study
    Zacks

    Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study

    Lilly (LLY) is conducting five studies on Olumiant (baricitinib) under the atopic dermatitis (AD) program and BREEZE-AD7 is the third study to be completed this year.

  • Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
    PR Newswire

    Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis

    INDIANAPOLIS , Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal ...

  • Business Wire

    Incyte to Present at Upcoming Investor Conferences

    Incyte Corporation announced today that it will present at the following investor conferences during the month of September:

  • Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
    Zacks

    Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer

    Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.

  • 3 Charts That Suggest Now Is the Time to Buy Into Biotech
    Investopedia

    3 Charts That Suggest Now Is the Time to Buy Into Biotech

    Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.

  • Does Incyte (NASDAQ:INCY) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does Incyte (NASDAQ:INCY) Have A Healthy Balance Sheet?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • GlobeNewswire

    BriaCell Appoints Richard J. Berman to Board of Directors

    BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.

  • Top Biotech Stocks for February 2019
    Investopedia

    Top Biotech Stocks for February 2019

    Biotech a thrilling industry for investors, and one with tremendous opportunity for gains, as shown in early 2019, but it is notably risky for investors, too.

  • Thomson Reuters StreetEvents

    Edited Transcript of INCY earnings conference call or presentation 30-Jul-19 12:00pm GMT

    Q2 2019 Incyte Corp Earnings Call

  • Incyte Corp (INCY) Q2 2019 Earnings Call Transcript
    Motley Fool

    Incyte Corp (INCY) Q2 2019 Earnings Call Transcript

    INCY earnings call for the period ending July 30, 2019.

  • The No. 1 Biotech Is Flirting With A Buy Point After Its Beat-And-Raise
    Investor's Business Daily

    The No. 1 Biotech Is Flirting With A Buy Point After Its Beat-And-Raise

    Incyte stock approached a buy point Tuesday after the top-rated biotech company crushed second-quarter sales and earnings estimates and raised its 2019 outlook for cancer treatment Jakafi.

  • Here's What You'll Want to Know About Incyte's Impressive Q2 Results
    Motley Fool

    Here's What You'll Want to Know About Incyte's Impressive Q2 Results

    The biotech beat Wall Street revenue and earnings estimates in Q2. And it could have more good news on the way.

  • Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y
    Zacks

    Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y

    Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.